Home > HIV Protease & > Darunavir Ethanolate

Darunavir Ethanolate

地瑞那韦乙醇,达芦那韦乙醇,TMC 114,TMC114,TMC-114,UIC-94017,UIC94017,UIC 94017,

Darunavir ethanolate (达芦那韦乙醇合物) 是HIV蛋白酶抑制剂。

目录号
EY1833
EY1833
EY1833
EY1833
纯度
99.44%
99.44%
99.44%
99.44%
规格
5 mg
10 mg
50 mg
100 mg
原价
495
780
2580
3980
售价
495
780
2580
3980
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Darunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Fujimoto H, et al. Biol Pharm Bull, 2009, 32(9), 1588-1593.
    [2] Laurent Mandelbrot,et al. Placental Transfer of Darunavir in an Ex Vivo Human Cotyledon Perfusion Model. Antimicrob Agents Chemother. 2014 Sep; 58(9): 5617–5620. doi: 10.1128/AAC.03184-14.
    [3] Yong Wang, Zhigang Liu,et al. The Higher Barrier of Darunavir and Tipranavir Resistance for HIV-1 Protease. Biochem Biophys Res Commun. Author manuscript; available in PMC 2012 Sep 9. Published in final edited form as: Biochem Biophys Res Commun. 2011 Sep 9; 412(4): 737–742. Published online 2011 Aug 17. doi: 10.1016/j.bbrc.2011.08.045

    分子式
    C29H43N3O8S    		 分子量
    593.73    		 CAS号
    635728-49-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    100 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02503462 AIDS-related Dementia Complex Drug: Darunavir|Drug: ritonavir|Drug: cobicistat University Hospital, Basel, Switzerland Phase 4 2015-07-01 2017-02-01
    NCT01606722 HIV-infection Drug: Darunavir/ritonavir Hospitales Universitarios Virgen del Roco 2010-01-01 2013-07-10
    NCT00885495 HIV Infections Drug: darunavir, ritonavir, rosuvastatin|Drug: rosuvastatin, darunavir, ritonavir University of Cincinnati Phase 1|Phase 2 2009-01-01 2009-04-21
    NCT02384967 HIV INFECTION Drug: Darunavir French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Phase 2 2015-03-01 2017-01-23
    NCT02187107 HIV Drug: TMC114|Drug: rtv Tibotec Pharmaceuticals, Ireland Phase 2 2005-01-01 2014-08-22
    NCT00855088 HIV/AIDS|HIV Infections Drug: darunavir|Drug: Ritonavir|Drug: Etravirine University of North Carolina, Chapel Hill|Tibotec Pharmaceutical Limited Phase 1 2009-07-01 2011-05-11
    NCT01047995 HIV Infections Drug: Raltegravir plus Darunavir/ritonavir|Drug: Raltegravir plus Darunavir/ritonavir St Stephens Aids Trust Phase 1 2009-06-01 2010-01-12
    NCT01741831 Acquired Immune Deficiency Syndrome Drug: No intervention Janssen Korea, Ltd., Korea Phase 4 2012-07-01 2016-12-02
    NCT00355524 HIV-1|HIV Infections Drug: TMC114|Drug: Ritonavir Tibotec Pharmaceuticals, Ireland Phase 2 2006-06-01 2013-07-05
    NCT00071097 HIV Infections Drug: TMC114/rtv|Drug: TMC114/rtv|Drug: TMC114/rtv|Drug: TMC114/rtv Tibotec Pharmaceuticals, Ireland Phase 2 2003-10-01 2016-09-19
    NCT01695954 Hyperlipidemia|HIV Drug: Pitavastatin|Drug: Darunavir|Drug: Ritonavir|Drug: Efavirenz New York University School of Medicine|Bellevue/NYU AIDS Clinical Trials Unit|Kowa Pharmaceuticals America, Inc.|University at Buffalo Phase 1 2012-05-01 2012-09-27
    NCT00081588 HIV Infection Drug: TMC114 Tibotec Pharmaceuticals, Ireland Phase 2 2003-11-01 2014-06-19
    NCT01375881 HIV Infections Drug: darunavir/ritonavir plus background regimen Janssen-Cilag S.p.A. Phase 4 2009-06-01 2013-05-03
    NCT01423812 HIV Drug: Twice-daily Darunavir/ritonavir|Drug: Once-daily Darunavir/ritonavir Ruth M. Rothstein CORE Center|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Phase 4 2012-01-01 2015-04-20
    NCT00855413 Acute HIV Infection|HIV Infections Drug: Darunavir/Ritonavir and Etravirine University of North Carolina, Chapel Hill|Janssen Pharmaceuticals Phase 4 2009-03-01 2014-10-14
    NCT00115050 HIV Infections Drug: TMC114 Tibotec Pharmaceuticals, Ireland Phase 3 2005-06-01 2011-06-02
    NCT00964327 HIV Infections Drug: TMC114 Tibotec Pharmaceuticals, Ireland Phase 2 2001-08-01 2011-05-18
    NCT00110877 HIV Infection Drug: LPV/rtv|Drug: TMC114/rtv Tibotec Pharmaceuticals, Ireland Phase 3 2005-04-01 2015-07-01
    NCT01258439 HIV|Cardiovascular Disease Drug: raltegravir plus truvada|Drug: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada) St Vincent's Hospital, Sydney|Merck Sharp & Dohme Corp. Phase 4 2010-11-01 2015-01-08
    NCT02671383 HIV Infections Drug: Darunavir|Drug: Lopinavir Willem Daniel Francois Venter|Medical Research Council, South Africa|University of Witwatersrand, South Africa Phase 3 2016-07-01 2016-07-11
    NCT00855335 HIV|HIV Infections|Pregnancy Drug: Darunavir|Drug: Ritonavir|Drug: Etravirine|Drug: Rilpivirine|Drug: Darunavir/Cobicistat (FDC) Janssen Scientific Affairs, LLC Phase 3 2009-04-01 2017-02-14
    NCT01702090 HIV-1 Drug: TMC114/ritonavir Janssen-Cilag Ltd. Phase 4 2012-02-01 2016-05-20
    NCT02499978 HIV/AIDS Drug: Darunavir/Cobicistat|Drug: Dolutegravir Stanford University|Janssen Scientific Affairs, LLC|University of Colorado, Denver Phase 2|Phase 3 2016-05-01 2016-10-27
    NCT01046890 HIV Infections Drug: Echinacea Germans Trias i Pujol Hospital|IrsiCaixa Phase 4 2010-01-01 2010-05-04
    NCT01541085 Human Immunodeficiency Virus; HIV Drug: Darunavir/Ritonavir (DRV/r)|Drug: Efavirenz (EFV) Janssen-Cilag S.p.A. Phase 4 2011-12-01 2013-11-25

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：